Skip to main content

Table 1 Characteristics of the study population

From: A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

Numerical variables

all patients

ART-naive

ART-experienced

  

median (IQR)

median (IQR)

median (IQR)

calendar year

2004 (2003-2006)

2006 (2004-2007)

2004 (2002-2005)

HIV-1 RNA log10 copies/ml

4.53 (3.83-5.12)

5.08 (4.63-5.5)

4.18 (3.63-4.8)

CD4+ count cells/mm3

273 (147-389)

191 (70-300)

296.8 (192-435)

Age years

40 (36-45)

39 (33-45)

40 (37-45)

GSS

Rega

3 (2-3)

3 (3-3)

2 (1.5-3)

 

ANRS

3 (2-3)

3 (3-3)

2 (1.5-3)

 

HIVdb

3 (2-3)

3 (3-3)

2 (1.5-3)

Categorical variables

n (%)

n (%)

n (%)

#patients

2158

733 (34.0%)

1425 (57.7%)

#cART regimens

2337

733 (31.4%)

1604 (68.6%)

cART type

2NRTI+1NNRTI

516 (23.9%)

235 (32.1%)

281 (19.7%)

 

2NRTI+1PI

243 (11.3%)

45 (6.1%)

198 (13.9%)

 

2NRTI+1PI/r

1306 (60.5%)

441 (60.2%)

865 (60.7%)

 

3NRTI

93 (4.3%)

12 (1.6%)

81 (5.7%)

gender

male

1546 (71.6%)

563 (76.8%)

983 (69%)

previous AIDS-defining events (yes vs. no)

285 (13.2%)

92 (12.6%)

193 (13.5%)

Nationality

Italian

1524 (70.6%)

529 (72.2%)

995 (69.8%)

 

non-Italian

168 (7.8%)

98 (13.4%)

70 (4.9%)

 

unknown

466 (21.6%)

106 (14.5%)

360 (25.3%)

mode of HIV-1 transmission

heterosexual

657 (30.4%)

262 (35.7%)

395 (27.7%)

 

male homosexual

362 (16.8%)

154 (21%)

208 (14.6%)

 

IDU

468 (21.7%)

54 (7.4%)

414 (29.1%)

 

other/unknown

671 (31.1%)

263 (35.9%)

408 (28.6%)

HBV/HCV co-infection

positive

605 (28%)

149 (20.3%)

456 (32%)

 

negative

483 (22.4%)

260 (35.5%)

223 (15.6%)

 

unknown

1070 (49.6%)

324 (44.2%)

746 (52.4%)

interval time from the first HIV-1 positive test to cART initiation

< = 12 months

444 (20.6%)

354 (48.3%)

90 (6.3%)

 

> 12 and < = 60 months

188 (8.7%)

45 (6.1%)

143 (10%)

 

> 60 months

575 (26.6%)

61 (8.3%)

514 (36.1%)

 

unknown

951 (44.1%)

273 (37.2%)

678 (47.6%)

duration of prior ART exposures

< = 6 months

1197 (55.5%)

733 (100%)

464 (32.6%)

 

> 6 and < = 12 months

117 (5.4%)

N/A

117 (8.2%)

 

> 12 and < = 24 months

184 (8.5%)

N/A

184 (12.9%)

 

> 24 months

660 (30.6%)

N/A

660 (46.3%)

viral subtype

B

1753 (81.2%)

503 (68.6%)

1250 (87.7%)

 

02_AG

56 (2.6%)

28 (3.8%)

28 (2%)

 

C

41 (1.9%)

31 (4.2%)

10 (0.7%)

 

F1

54 (2.5%)

39 (5.3%)

15 (1.1%)

 

other

60 (2.8%)

35 (4.8%)

25 (1.8%)

 

undetermined

194 (9%)

97 (13.2%)

97 (6.8%)

#previous ART switches

none

733 (34%)

733 (100%)

N/A

 

one/two

429 (19.9%)

N/A

429 (30.1%)

 

three to six

605 (28%)

N/A

605 (42.5%)

 

more than six

391 (18.1%)

N/A

391 (27.4%)

previous exposure to suboptimal ART (yes vs. no)

922 (42.7%)

N/A

922 (64.7%)

previous ART class exposure

none

733 (34%)

733 (100%)

N/A

 

only NRTI

94 (4.4%)

N/A

94 (6.6%)

 

NRTI and NNRTI

220 (10.2%)

N/A

220 (15.4%)

 

NRTI, NNRTI and PI

252 (11.7%)

N/A

252 (17.7%)

 

NRTI, NNRTI and PI/r

466 (21.6%)

N/A

466 (32.7%)

 

NRTI and PI

229 (10.6%)

N/A

229 (16.1%)

 

NRTI and PI/r

134 (6.2%)

N/A

134 (9.4%)

 

other classes

30 (1.4%)

N/A

30 (2.1%)

  1. *cART: combination antiretroviral therapy; GSS: genotypic susceptibility score; ART: antiretroviral therapy; NRTI: nucleoside/tide reverse transcriptase inhibitors; NNRTI: non-nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus.